SS-31 (Elamipretide) Mechanism of Action
How SS-31 (Elamipretide) works: receptor targets, signalling pathways, and molecular profile.
Targeting the Inner Mitochondrial Membrane
SS-31 is a small, positively-charged tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it binds and stabilizes cardiolipin — a lipid essential to the structure of the electron transport chain and efficient ATP production. Stabilizing cardiolipin is thought to reduce electron leakage and reactive oxygen species production in dysfunctional mitochondria.
A Narrow, Real Approval
SS-31 (as elamipretide) received FDA approval in September 2025 specifically for Barth syndrome, a rare inherited mitochondrial disease causing muscle weakness and cardiomyopathy. This is a genuine regulatory approval, not a research-community claim — but it applies to one narrow, rare population, not muscle function or mitochondrial health broadly.